Lasseter KC

References (5)

Title : Sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not affect the pharmacokinetics of ethinyl estradiol or norethindrone in healthy female subjects - Migoya_2011_J.Clin.Pharmacol_51_1319
Author(s) : Migoya E , Larson P , Bergman A , Miller J , Johnson-Levonas AO , Lasseter KC , Wagner JA
Ref : Journal of Clinical Pharmacology , 51 :1319 , 2011
Abstract :
PubMedSearch : Migoya_2011_J.Clin.Pharmacol_51_1319
PubMedID: 21209231

Title : Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension - Mistry_2008_J.Clin.Pharmacol_48_592
Author(s) : Mistry GC , Maes AL , Lasseter KC , Davies MJ , Gottesdiener KM , Wagner JA , Herman GA
Ref : Journal of Clinical Pharmacology , 48 :592 , 2008
Abstract :
PubMedSearch : Mistry_2008_J.Clin.Pharmacol_48_592
PubMedID: 18353996

Title : The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin - He_2007_Eur.J.Clin.Pharmacol_63_677
Author(s) : He YL , Sabo R , Campestrini J , Wang Y , Ligueros-Saylan M , Lasseter KC , Dilzer SC , Howard D , Dole WP
Ref : European Journal of Clinical Pharmacology , 63 :677 , 2007
Abstract :
PubMedSearch : He_2007_Eur.J.Clin.Pharmacol_63_677
PubMedID: 17486328

Title : Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes - Herman_2006_J.Clin.Endocrinol.Metab_91_4612
Author(s) : Herman GA , Bergman A , Stevens C , Kotey P , Yi B , Zhao P , Dietrich B , Golor G , Schrodter A , Keymeulen B , Lasseter KC , Kipnes MS , Snyder K , Hilliard D , Tanen M , Cilissen C , De Smet M , De Lepeleire I , Van Dyck K , Wang AQ , Zeng W , Davies MJ , Tanaka W , Holst JJ , Deacon CF , Gottesdiener KM , Wagner JA
Ref : J Clinical Endocrinology Metab , 91 :4612 , 2006
Abstract :
PubMedSearch : Herman_2006_J.Clin.Endocrinol.Metab_91_4612
PubMedID: 16912128

Title : Population pharmacokinetics and pharmacodynamics of pyridostigmine bromide for prophylaxis against nerve agents in humans - Marino_1998_J.Clin.Pharmacol_38_227
Author(s) : Marino MT , Schuster BG , Brueckner RP , Lin E , Kaminskis A , Lasseter KC
Ref : Journal of Clinical Pharmacology , 38 :227 , 1998
Abstract :
PubMedSearch : Marino_1998_J.Clin.Pharmacol_38_227
PubMedID: 9549661